HPGC(SH:600664) Zhi Tong Cai Jing·2026-02-10 08:08Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) announced that its subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory (哈药总厂), received approval from the National Medical Products Administration for the injectable Cefoperazone Sodium, indicating successful consistency evaluation of quality and efficacy for generic drugs [1]. Group 1 - The approved injectable Cefoperazone Sodium is available in two dosages: 1.0g and 0.5g, with respective notification numbers 2026B00713 and 2026B00715 [1]. - Cefoperazone Sodium is indicated for infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, gynecological infections, bacteremia/sepsis, skin and soft tissue infections, abdominal infections, bone and joint infections, and central nervous system infections [1].